Phathom Pharmaceuticals, Inc. (PHAT) is a late clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases. It was founded in 2018 and has been publicly traded on the New York Stock Exchange (NYSE) under the ticker "PHAT" since October 2019. The company's primary focus lies in treating health conditions that are in dire need of improved therapy options, striving to elevate the standard of care and enhance patients' quality of life.
The company's lead product is Vonoprazan, an oral potassium-competitive acid blocker (P-CAB), a type of medicine that helps decrease the amount of acid produced by the stomach, with distinct characteristics that mark it out in the acid reflux disease marketplace. Phathom holds exclusive rights to develop and market Vonoprazan in the United States, Europe, and Canada under a licensing agreement with Takeda Pharmaceutical Company. Vonoprazan is currently under Phase 3 trials and being evaluated for erosive esophagitis, a condition that involves the inflammation of the esophagus, and for use in the treatment of Helicobacter pylori (H. pylori) infection, a common chronic bacterial infection of the stomach lining and underlying mucosa which can contribute to the development of certain types of stomach cancer.
Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, with a corporate office in Buffalo Grove, Illinois. The company has brought together a highly experienced team of professionals from the biopharmaceutical industry to guide its growth and development. As of 2021, it also boasts a strategic partnership with EA Pharma, a gastroenterology-focused pharmaceutical company in Japan, to co-develop Vonoprazan in select Asian markets.
Despite being a young company, Phathom Pharmaceuticals has shown strong potential, particularly in dealing with gastrointestinal diseases. Its robust approach to developing safe and efficient medications aims to revolutionize the healthcare market and provide meaningful solutions for patients suffering from gastrointestinal diseases. As it progresses towards the commercial introduction of its leading candidate, Vonoprazan, the company is poised to make significant contributions to the medical field.